
“Full Analysis of Patient Recruitment” for ImmuPharma PLC Phase III clinical trial of Lupuzor
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, has given DirectorsTalk further details of patient participation following confirmation (as announced on 22 December 2016) that the Company had